Meeting Coverage:

American Academy of Ophthalmology

AAO: 2021

Skip 4-Week Dosing With Brolucizumab

Show Description +

Arshad M. Khanani, MD, explains the results from the Phase 3a MERLIN trial of brolucizumab in patients with wet AMD; the therapy had superior drying effects, but an increased rate of adverse events.

Posted: 11/17/2021

Up Next


Home-Based Glaucoma Monitoring

Oluwatosin U. Smith, MD

Skip 4-Week Dosing With Brolucizumab

Arshad M. Khanani, MD, explains the results from the Phase 3a MERLIN trial of brolucizumab in patients with wet AMD; the therapy had superior drying effects, but an increased rate of adverse events.

Posted: 11/17/2021


Please log in to leave a comment.